Retail Offer to raise up to £0.5 million

Aptamer Group plc (AIM:APTA) has announced a retail offer to raise up to £0.5 million by issuing new ordinary shares at an issue price of 0.6 pence each. This initiative is part of a broader fundraising strategy that includes a conditional placing and subscription that has already secured approximately £4.275 million. The retail offer will allow existing shareholders in the UK to participate through financial intermediaries registered with BookBuild, with each participant receiving one warrant for every three shares subscribed, exercisable at a 50% premium to the issue price. The admission of the new shares to trading on AIM is anticipated around April 16, 2026, contingent upon shareholder approval at a General Meeting scheduled for April 13, 2026.

The proceeds from this retail offer will be allocated for the same purposes as the funds raised through the previously announced placing and subscription. The first tranche of the placing, amounting to approximately £1.38 million, is expected to complete by March 31, 2026, while the second tranche, along with the subscription, is projected to complete around April 16, 2026. This structured approach to fundraising indicates a strategic alignment in the company’s financial planning, as it seeks to bolster its capital base to support ongoing operations and future growth initiatives.

Aptamer Group currently has a market capitalisation of £17.6 million. The company is positioned within the life sciences sector, focusing on the development of next-generation synthetic binders. This niche market is characterized by significant competition and innovation, particularly as companies strive to enhance the efficacy and specificity of biomolecular interactions. The retail offer, while modest in size relative to the total fundraising effort, reflects a proactive approach to engaging retail investors, which can enhance shareholder loyalty and broaden the company's investor base.

In terms of financial positioning, the company’s capital structure is being strengthened through this fundraising effort, which is critical given the competitive landscape in the life sciences sector. The total gross proceeds from the retail offer, placing, and subscription will amount to approximately £4.775 million, which should provide a substantial runway for operational activities. However, the dilution risk associated with the issuance of new shares and warrants must be carefully considered. The issuance of up to 83,333,333 new ordinary shares will increase the total share count, potentially impacting existing shareholders' equity stakes. The warrants, while providing an incentive for participation, also represent a future dilution risk if exercised.

Valuation metrics for Aptamer Group can be compared against direct peers in the life sciences sector, particularly those involved in similar stages of development. However, identifying direct peers within the same market cap tier and operational focus can be challenging. Companies such as Abcam plc (AIM:ABC), which operates in a related space, and other similarly sized life sciences firms, may provide a reference point for valuation. For instance, Abcam has been noted for its strong market presence and innovative product offerings, which could serve as a benchmark for Aptamer's valuation in terms of EV/EBITDA or revenue multiples. Given the market cap of Aptamer at £17.6 million, it would be prudent to consider peers with market caps ranging from approximately £4.4 million to £70.4 million.

Execution risk remains a critical factor for Aptamer Group, particularly as it navigates the complexities of the life sciences market. The company has set ambitious goals for its product development pipeline, and any delays or setbacks could impact investor confidence and future funding opportunities. The upcoming General Meeting on April 13, 2026, will be a pivotal moment for the company, as shareholder approval is necessary for the retail offer to proceed. Additionally, the successful completion of the placing and subscription is not contingent upon the retail offer, which adds a layer of complexity to the overall fundraising strategy.

In conclusion, the announcement of the retail offer is classified as moderate in materiality. While it represents a strategic move to enhance the company’s capital base, the associated dilution risks and execution uncertainties cannot be overlooked. The upcoming shareholder meeting and the anticipated admission of new shares will be key catalysts for Aptamer Group, as they seek to solidify their position in the competitive life sciences sector. The overall fundraising strategy, if executed successfully, could provide the necessary resources to support the company's growth ambitions and innovation initiatives.

Key insights

• ●Retail offer aims to raise £0.5 million at 0.6 pence per share.
• ●Total fundraising effort reaches £4.775 million.
• ●Upcoming General Meeting on April 13, 2026, is crucial for approval.

Disagree with this article?